Physician profile
Lilly Ramirez-Boyd
NPI 1386663862
$3,075.59
in general payments reported to CMS, 2019-2025
27 companies · $142 in 2025
The $142 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $393 · 2021: $527 · 2022: $441 · 2023: $317 · 2024: $439 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.15 | 2019-2025 | |
| Upsher-Smith Laboratories LLC | $562.16 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $409.28 | 2021-2025 | |
| Hologic Sales and Service, LLC | $157.01 | 2019-2023 | Aptima |
| Eisai INC. | $120.35 | 2024 | |
| Amgen INC. | $119.46 | 2019-2022 | |
| Allergan, INC. | $114.77 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $110.00 | 2024 | Enhertu |
| Tesaro, INC. | $105.40 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $94.74 | 2022 | |
| Seagen INC. | $92.06 | 2022 | |
| Therapeuticsmd, INC. | $70.89 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $62.88 | 2021-2022 | |
| Pfizer INC. | $60.30 | 2021-2025 | |
| Myovant Sciences INC. | $49.08 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $42.90 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $42.81 | 2019 | |
| Exeltis, USA INC. | $36.80 | 2024-2025 | Slynd |
| Dexcom, INC. | $28.31 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $23.82 | 2024 | Zejula, Jemperli |
| Lundbeck LLC | $21.09 | 2025 | Vyepti |
| Daiichi Sankyo INC. | $19.88 | 2019 | |
| Lilly USA, LLC | $19.41 | 2025 | Zepbound |
| Assertio Therapeutics, INC. | $16.91 | 2020 | |
| Almatica Pharma LLC | $13.76 | 2021 | |
| Lupin INC. | $13.66 | 2019 | |
| Sumitomo Pharma America, INC. | $12.71 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilly Ramirez-Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.